A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for TriSalus Life Sciences's Debt-to-EBITDA or its related term are showing as below:
TLSI'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.65 Med: -0.47 Max: -0.03
Current: -1.65
During the past 5 years, the highest Debt-to-EBITDA Ratio of TriSalus Life Sciences was -0.03. The lowest was -1.65. And the median was -0.47.
TLSI's Debt-to-EBITDA is ranked worse than 100% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 1.555
vs TLSI: -1.65
TriSalus Life Sciences (NAS:TLSI) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
TriSalus Life Sciences Debt-to-EBITDA Related Terms
TriSalus Life Sciences Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for TriSalus Life Sciences's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TLSI vs TMCI, LAB, SENS: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, TriSalus Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
TriSalus Life Sciences (TLSI) has a Debt-to-EBITDA of 2.77 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on TriSalus Life Sciences. According to the industry distribution chart, TriSalus Life Sciences ranks #999999 out of 468 companies in the Medical Devices & Instruments industry.
Is TriSalus Life Sciences' Debt-to-EBITDA too high?
TriSalus Life Sciences' current Debt-to-EBITDA is 2.77. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.56. TriSalus Life Sciences' value of 2.77 is 78.1% above this industry median. Based on the distribution chart, TriSalus Life Sciences ranks #999999 out of 468 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TriSalus Life Sciences has a GF Score™ of 29/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Debt-to-EBITDA compare to TMCI and LAB?
According to the Medical Devices & Instruments industry distribution chart, TriSalus Life Sciences ranks #999999 out of 468 companies for Debt-to-EBITDA. This places TriSalus Life Sciences in the lower half of its industry. The industry median Debt-to-EBITDA is 1.56. TriSalus Life Sciences' value of 2.77 is 78.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.56, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TriSalus Life Sciences's current Debt-to-EBITDA of 2.77 is 78.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on TriSalus Life Sciences. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TriSalus Life Sciences's current Debt-to-EBITDA is 2.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.31, compared to a current price of $3.82 — trading 11.4% below its estimated fair value. The current Debt-to-EBITDA is 2.77 and 78.1% above the Medical Devices & Instruments industry median of 1.56. TriSalus Life Sciences' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Debt-to-EBITDA is 2.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TriSalus Life Sciences (TLSI) Overvalued in 2026?
Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be undervalued.
The current stock price of $3.82 is trading 11.4% below its estimated GF Value™ of $4.31.
GuruFocus considers TriSalus Life Sciences to be Modestly Undervalued.
Key valuation signals for TLSI:
Debt-to-EBITDA: 2.77
GF Value™: $4.31 vs. price of $3.82 (11.4% below fair value)
Industry Position: 78.1% above the Medical Devices & Instruments median (#999999 of 468)
No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
29GF Score
Get the complete analysis for TLSI
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSI has been successfully added to your 
